How should lorazepam be prescribed for short‑term relief of anxiety or insomnia in an adult without severe hepatic impairment, substance‑use disorder, pregnancy, breastfeeding, or uncontrolled narrow‑angle glaucoma?

How to Prescribe Lorazepam

For short-term relief of anxiety in adults, prescribe lorazepam 2-3 mg/day divided into 2-3 doses (typically 0.5-1 mg per dose), with the largest dose at bedtime; for insomnia, prescribe a single dose of 2-4 mg at bedtime. 1

Dosing Algorithm

For Anxiety

• Standard adult dose: Start with 2-3 mg/day divided into 2-3 doses (e.g., 1 mg twice daily or three times daily)
• Elderly or debilitated patients: Start with 1-2 mg/day in divided doses, adjust as tolerated 1
• Maximum daily dose: Generally 4 mg/day for anxiety (up to 10 mg/day in select cases) 2
• Take the largest dose before bedtime to minimize daytime sedation 1

For Insomnia

• Single bedtime dose: 2-4 mg at bedtime for insomnia due to anxiety or transient situational stress 1
• Elderly patients: Reduce to 0.25-0.5 mg (maximum 2 mg in 24 hours) 2
• Lorazepam is not a first-line agent for chronic insomnia—FDA-approved benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon, temazepam) or ramelteon should be preferred 3

When to Consider Lorazepam

Lorazepam may be appropriate when:

• The patient has episodic or acute anxiety requiring rapid onset of action 4
• Comorbid conditions exist that might benefit from lorazepam's intermediate duration of action 3
• The patient requires as-needed dosing for anxiety or agitation 2
• First-line agents for insomnia have failed and the patient's symptom pattern matches lorazepam's pharmacokinetic profile 3

Important caveat: Lorazepam is not specifically FDA-approved for insomnia, though it may be considered if the duration of action is appropriate for the patient's presentation 3. For chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) should be the initial intervention, with FDA-approved hypnotics (non-benzodiazepine receptor agonists) as first-line pharmacotherapy 3, 5.

Administration Instructions

• Oral concentrate formulation: Mix with liquid (water, juice, soda) or semi-solid food (applesauce, pudding) using the calibrated dropper provided 1
• Consume the entire mixture immediately—do not store for future use 1
• Timing: Take on an empty stomach when possible to maximize effectiveness 3
• Dose escalation: When higher doses are needed, increase the evening dose first before increasing daytime doses 1

Duration of Treatment

Lorazepam should be prescribed for short-term use only—ideally a few days to 2 weeks maximum, occasionally up to 4 weeks 3, 6. The evidence supporting long-term benzodiazepine use is insufficient, and risks of dependence, tolerance, and withdrawal increase substantially with prolonged use 3, 5, 7.

• Short-term anxiety: 1-7 days or 2-4 weeks maximum 6
• Insomnia: Limit to a few days, occasional/intermittent use, or courses not exceeding 2 weeks 3
• Long-term use (>4 weeks) is only justified in patients with chronic severe anxiety where symptomatic relief outweighs dependence risk 4

Patient Education Requirements

Before prescribing, counsel patients on 3, 1:

1. Treatment goals and realistic expectations: Lorazepam provides symptom relief but does not address underlying causes
2. Safety concerns:
   • Never combine with opioids, alcohol, or other CNS depressants—risk of severe respiratory depression, coma, and death 1
   • Avoid driving or operating heavy machinery until effects are known 1
3. Potential side effects: Sedation, dizziness, weakness, unsteadiness, cognitive impairment 1
4. Risk of dependence: Even at prescribed doses, physical dependence can develop 1
5. Withdrawal risks: Abrupt discontinuation can cause seizures, severe mental status changes, and life-threatening symptoms 1
6. Rebound insomnia/anxiety: Symptoms may temporarily worsen after stopping 3

Monitoring and Follow-Up

• Initial phase: Follow up every few weeks to assess effectiveness, side effects, and need for ongoing medication 3
• Ongoing: Use the lowest effective maintenance dose 3
• Reassess regularly: If insomnia/anxiety does not remit within 7-10 days, further evaluation is needed to identify underlying causes 7

Discontinuation Protocol

Never stop lorazepam abruptly. Use a gradual taper to reduce withdrawal risk 1:

• If withdrawal symptoms emerge, pause the taper or increase back to the previous dose level
• Subsequently decrease more slowly
• Consider combining with CBT-I to facilitate medication tapering 3

Critical Safety Warnings

Absolute Contraindications

• Known allergy to lorazepam or other benzodiazepines 1
• Acute narrow-angle glaucoma (per general benzodiazepine contraindications)

Use with Extreme Caution

• Respiratory compromise: COPD, sleep apnea—benzodiazepines can worsen respiratory depression 3, 1
• Hepatic impairment: Dose reduction may be needed (though lorazepam undergoes glucuronidation and is relatively safer than other benzodiazepines in liver disease)
• Renal impairment: If eGFR <30 mL/min, consider alternative agents 2
• Elderly patients: Increased risk of falls, fractures, cognitive impairment, and paradoxical agitation 3—start with lower doses (0.25-0.5 mg) 2
• Depression or suicidal ideation: Pre-existing depression may worsen; monitor closely 1
• History of substance use disorder: High risk of misuse and addiction 1

Drug Interactions

• Opioids: Potentially fatal respiratory depression—avoid combination 1
• Other CNS depressants: Additive sedation and psychomotor impairment 3
• Alcohol: Severe interaction—patients must abstain 1

Special Populations

Pregnancy and Breastfeeding

• Pregnancy: Lorazepam may harm the fetus—discuss risks/benefits carefully 1
• Breastfeeding: Lorazepam passes into breast milk; do not breastfeed while taking lorazepam 1. Recent pharmacokinetic data suggest low infant exposure with occasional single low doses, but routine use is not recommended 8

Elderly

• Start with 1-2 mg/day divided doses (or 0.25-0.5 mg for acute anxiety/agitation) 2, 1
• Maximum 2 mg/24 hours for acute management 2
• Higher risk of cognitive impairment, falls, and paradoxical reactions 3

Common Pitfalls to Avoid

1. Prescribing for chronic insomnia without trying CBT-I or FDA-approved hypnotics first: Lorazepam is not first-line for insomnia 3, 5, 9
2. Failing to set duration limits at initial prescription: Clearly communicate short-term use (days to 2 weeks) 3, 6
3. Combining with opioids or alcohol: This is potentially fatal 1
4. Abrupt discontinuation: Always taper gradually 1
5. Ignoring underlying causes: If anxiety/insomnia persists beyond 7-10 days, investigate comorbid conditions (depression, sleep apnea, substance use, medical causes) 7
6. Overlooking cognitive/behavioral therapies: Pharmacotherapy should supplement, not replace, behavioral interventions when possible 3

Comparative Context

While lorazepam has intermediate duration of action and may be useful for episodic anxiety 4, newer non-benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) are preferred for insomnia due to better safety profiles and FDA approval for this indication 3, 9. For chronic anxiety, consider SSRIs/SNRIs as first-line with benzodiazepines reserved for acute exacerbations or initial bridging therapy 3.